@article {2020.09.12.20192922, author = {The Schizophrenia Working Group of the Psychiatric Genomics Consortium and Stephan Ripke and James TR Walters and Michael C O{\textquoteright}Donovan}, title = {Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia}, elocation-id = {2020.09.12.20192922}, year = {2020}, doi = {10.1101/2020.09.12.20192922}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Schizophrenia is a psychiatric disorder whose pathophysiology is largely unknown. It has a heritability of 60-80\%, much of which is attributable to common risk alleles, suggesting genome-wide association studies can inform our understanding of aetiology1. Here, in 69,369 people with schizophrenia and 236,642 controls, we report common variant associations at 270 distinct loci. Using fine-mapping and functional genomic data, we prioritise 19 genes based on protein-coding or UTR variation, and 130 genes in total as likely to explain these associations. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in autism and developmental disorder. Associations were concentrated in genes expressed in CNS neurons, both excitatory and inhibitory, but not other tissues or cell types, and implicated fundamental processes related to neuronal function, particularly synaptic organisation, differentiation and transmission. We identify biological processes of pathophysiological relevance to schizophrenia, show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders, and provide a rich resource of priority genes and variants to advance mechanistic studies.Competing Interest StatementAarno Palotie is a member of Astra Zenecas Genomics Advisory Board. Veikko Salomaa has consulted for Novo Nordisk and has ongoing research collaboration with Bayer Ltd (both unrelated to the present study). Michael Green is a paid consultant for AiCure, Biogen, Lundbeck, and Roche, is a member of the Scientific Board of Cadent, and has received research funds from Forum. Gregory Light has consulted to Astellas, Forum, and Neuroverse Keith Nuechterlein has research support from Janssen, Genentech, and Brain Plasticity Inc. Also has consulted to Astellas, MedinCell, Takeda, Teva, Genentech, Otsuka, Janssen, and Brain Plasticity Inc. David Cohen has reported past consultation for or the receipt of honoraria from Otsuka, Shire, Lundbeck, Roche and Janssen. Mark Daly is a founder of Maze Therapeutics. Anil K. Malhotra is a consultant to Genomind Inc, InformedDNA, and Concert Pharmaceuticals. Rodrigo Affonseca Bressan has received research grants from Janssen; has been a forum consultant for Janssen and Sanof; Roche; speaker bureau for Ache, Janssen, Sanofi and Torrent. Cristiano Noto was on the speakers{\textquoteright} bureau and/or has acted as a consultant for Janssen and Daiichi-Sankyo in the last 12 months. Christos Pantelis has, for the last 3 years, served on an advisory board for Lundbeck and received honoraria for talks presented at educational meetings organized by Lundbeck. David A Collier is a full-time employee and stockholder of Eli Lilly and Company. Michael O{\textquoteright}Donovan is supported by a collaborative research grant from Takeda Pharmaceuticals. Michael Owenis supported by a collaborative research grant from Takeda Pharmaceuticals. James Walters is supported by a collaborative research grant from Takeda Pharmaceuticals. Andrew Pocklington is supported by a collaborative research grant from Takeda Pharmaceuticals. Stephen R. Marder has consulted for the following companies: Roche, Sunovion, Lundbeck, Boeringer-Ingelheim, Acadia, and Merck. Srihari Gopal is a full time employee and shareholder Johnson \& Johnson (AMEX: JNJ). Adam Savitz is an employee of Janssen Research \& Development, LLC and own stock/stock options in the company. Qingqin Li is an employee of Janssen Research \& Development, LLC and own stock/stock options in the company. Tony Kham-Thong is an employee of F.Hoffman-La Roche Anna Rautanen is an employee of F.Hoffman-La Roche Dheeraj Malhotra is an employee of F.Hoffman-La Roche Sara Paciga is an employee of Pfizer Inc.Funding StatementThe National Institute of Mental Health (USA) provides core funding for the Psychiatric Genomics Consortium was Award Number U01MH109514. The work of the contributing groups was supported by numerous grants from governmental and charitable bodies as well as philanthropic donation (details to be provided). S.X. also gratefully acknowledges the support of the National Natural Science Foundation of China (NSFC) grant (31525014, 91731303, 31771388, 31961130380, and 32041008), the UK Royal Society-Newton Advanced Fellowship (NAF\R1\191094), Key Research Program of Frontier Sciences (QYZDJ-SSW-SYS009) and the Strategic Priority Research Program (XDB38000000) of the Chinese Academy of Sciences, and the Shanghai Municipal Science and Technology Major Project (2017SHZDZX01). This study is supported by Research Council of Norway (283798, 262656, 248980, 273291, 248828, 248778, 223273); KG Jebsen Stiftelsen, South-East Norway Health Authority, EU H2020 $\#$ 847776. Dr. Faraone is supported by the European Unions Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602805, the European Unions Horizon 2020 research and innovation programme under grant agreements No 667302 \& 728018 and NIMH grants 5R01MH101519 and U01 MH109536-01. This study was supported by FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil) - Grant numbers: 2010/08968-6 (S.I.B.); 2014/07280-1 (S.I.B.); 2007/58736-1 (M.AC.S.); 2011/50740-5 (R.A.B.); 2016/04983-7 (J.J.M.); 10/19176-3 (V.K.O. \& S.I.B.); 12/12686-1 (M.L.S. \& S.I.B.); CAPES - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Code 001. The Singapore team (Lee Jimmy, Liu Jianjun, Sim Kang, Chong Siow Chong, Mythily Subramanian) acknowledges the National Medical Research Council Translational and Clinical Research Flagship Programme (grant number: NMRC/TCR/003/2008). Supported by LM2018132, CZ.02.1.01/0.0/0.0/18_046/0015515 and IP6003-VZFNM00064203 to MM Jr. Dr. Arango has been funded by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, "A way of making Europe", CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program; and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundacion Familia Alonso and Fundacion Alicia Koplowitz. E. Bramon was supported by the Medical Research Council (G0901310 and G1100583), the Wellcome Trust (085475/B/08/Z, 085475/Z/08/Z), Mental Health Research UK, British Medical Associations Margaret Temple Fellowship, and the NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London. M.Dolores Molto is funded by the European Regional Development Fund (ERDF)-Valencian Community 2014-2020, Spain. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical details of each of the 90 studies are given in the supplementary "Cohort Descriptions".All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClumped and genome-wide summary statistics are available at the PGC UNC link provided below. https://www.med.unc.edu/pgc/download-results/}, URL = {https://www.medrxiv.org/content/early/2020/09/13/2020.09.12.20192922}, eprint = {https://www.medrxiv.org/content/early/2020/09/13/2020.09.12.20192922.full.pdf}, journal = {medRxiv} }